January 2026

Jazz Pharmaceuticals

44th Annual J.P. Morgan Healthcare Conference

Redefining Possibilities in Rare Disease

Renee Gala, President & CEO

Transforming Lives. Redefining Possibilities.

Caution Concerning Forward-Looking Statements

This presentation contains forward-looking statements and financial targets, including, but not limited to, statements related to: the Company's growth prospects and future financial and operating results, including the ability of the Company's portfolio to drive long-term shareholder value; expectations with respect to indication expansion opportunities; 2025 total revenue guidance and 2025 revenue for each of Xywav, Epidiolex and Modeyso and the Company's expectations related thereto; the Company's ability to drive significant cash flow generation; the Company's commercial expectations, including with respect to revenue diversification and its expectations for significant growth; the Company's expectations with respect to the commercial potential of its products and product candidates, including the peak potential of zanidatamab and Modeyso, growth opportunities for Epidiolex/Epidyolex, Modeyso, Xywav, Zepzelca and Ziihera, and the potential regulatory paths related thereto; the value and growth potential of its products; the Company's net product sales and goals for net product sales from new and acquired products; the Company's views and expectations relating to its patent portfolio, including with respect to expected patent protection; planned or anticipated clinical trial events, including with respect to initiations, enrollment and data read-outs, and the anticipated timing thereof, and planned or anticipated regulatory submissions and filings and other regulatory matters, including potential approvals, including the timing thereof, such as the timing of the supplemental biologics license application for, and launch and approval of, zanidatamab in 1L GEA; and other statements that are not historical facts. These forward-looking statements are based on the Company's current plans, objectives, estimates, expectations and intentions and inherently involve significant risks and uncertainties.

Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties associated with: maintaining or increasing sales of and revenue from Xywav, Zepzelca, Epidiolex / Epidyolex, Modeyso, Ziihera and other key marketed products; effectively launching and commercializing the Company's other products and product candidates; the successful completion of development and regulatory activities with respect to the Company's product candidates; obtaining and maintaining adequate coverage and reimbursement for the Company's products; the time-consuming and uncertain regulatory approval process, including the risk that the Company's current and/or planned regulatory submissions may not be submitted, accepted or approved by applicable regulatory authorities in a timely manner or at all, including the risk that the Company's supplemental biologics license application submission for zanidatamab in 1L GEA may not be approved in a timely manner or at all; the costly and time-consuming pharmaceutical product development and the uncertainty of clinical success, including risks related to failure or delays in successfully initiating or completing clinical trials and assessing patients; global economic, financial, and healthcare system disruptions and the current and potential future negative impacts to the Company's business operations and financial results; protecting and enhancing the Company's intellectual property rights and the Company's commercial success being dependent upon its obtaining, maintaining and defending intellectual property protection for its products and product candidates; delays or problems in the supply or manufacture of the Company's products and product candidates; complying with applicable U.S. and non-U.S. regulatory requirements, including those governing the research, development, manufacturing and distribution of controlled substances; government investigations, legal proceedings and other actions; identifying and consummating corporate development transactions, financing these transactions and successfully integrating acquired product candidates, products and businesses; the Company's ability to realize the anticipated benefits of its collaborations and license agreements with third parties; the sufficiency of the Company's cash flows and capital resources; the Company's ability to achieve targeted or expected future financial performance and results and the uncertainty of future tax, accounting and other provisions and estimates; the Company's ability to meet its projected long-term goals and objectives, in the time periods that the Company anticipates, or at all, and the inherent uncertainty and significant judgments and assumptions underlying the Company's long-term goals and objectives; the completion of financial closing procedures, final audit adjustments and other developments that may arise that would cause the Company's expectations with respect to the Company's 2025 revenue guidance to differ, perhaps materially, from the financial results that will be reflected in the Company's audited consolidated financial statements for the fiscal year ended December 31, 2025; and other risks and uncertainties affecting the Company, including those described from time to time under the caption "Risk Factors" and elsewhere in the Company's Securities and Exchange Commission filings and reports, including the Company's Annual Report on Form 10-K for the year ended December 31, 2024 as supplemented by the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, and its future filings and reports. Other risks and uncertainties of which the Company is not currently aware may also affect its forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated. The forward-looking statements made in this presentation are made only as of the date hereof or as of the dates indicated in the forward-looking statements, even if they are subsequently made available by the Company on its website or otherwise. The Company undertakes no obligation to update or supplement any forward-looking statements to reflect actual results, new information, future events, changes in its expectations or other circumstances that exist after the date as of which the forward-looking statements were made.

Strong Momentum from an Outstanding 2025

Research and Development

ZIIHERA® zanidatamab

Practice-changing 1L GEA data derisks **$2B+ opportunity**

ZEPZELCA™ (lurbinectedin)

Showcased **strong combination data** at ASCO in 1LM ES-SCLC

Commercial

MODEYSO™ (dordaviprone) capsules 125 mg

Rapid approval[1] **/ launch** exceeding expectations

ZEPZELCA™ (lurbinectedin)

Received **FDA approval and launched** in 1LM ES-SCLC[2]

Epidiolex® (cannabidiol)

Achieved **$1B+ sales**[3]

Achieved 2025 total revenue guidance[3,4]

Corporate Development

CHIMERIX **Acquisition**

Added Modeyso and neuro-oncology expertise

saniona™

Licensing agreement builds on epilepsy franchise

Corporate

Epidiolex® (cannabidiol)

Settled outstanding ANDA litigation = **durability into the very-late 2030's**

Resolved sleep litigation, removing uncertainty

Successful CEO transition

Reduced leverage with $750M debt paydown

Increased equity value **by $2.8 billion**[5]

[1]Received accelerated approval by FDA on August 6, 2025; [2]FDA approval of Zepzelca in combination with Tecentriq (atezolizumab) as first-line maintenance therapy for ES-SCLC; [3]Jazz Pharmaceuticals plc has not finalized its financial results for the year ended December 31, 2025, and actual results may differ; [4]The company expects that for the year ended December 31, 2025, reported total revenues will meet the guidance range provided on November 5, 2025; [5]Equity value increase YE2025 vs. YE2024.

Our Evolution as a Successful Rare Disease Company

2003 - 2013

~$900M in revenue concentrated on Xyrem

Built commercial capabilities

Created significant shareholder value

2014 - 2025

Over $4B in revenue

Diversified revenue base with three $1B+ franchises[1]

Increased R&D capabilities

Maintained stable equity value

2026 and Beyond

Deepen and expand commitment to rare disease

Leverage and strengthen key capabilities built over 20+ years

Realize full potential of existing assets and expand portfolio strategically

Build stronger and more valuable company

[1]Three $1B+ franchises include: rare sleep, rare epilepsy, and rare oncology.

Refined Strategic Focus on Rare Disease

Playing to Jazz's Strategic Advantages

RARE ONCOLOGY

RARE EPILEPSY

RARE SLEEP

NEW RARE THERAPEUTIC AREAS

Refined Strategic Focus on Rare Disease

Attractive Growth Market That Plays to Jazz's Strengths

RARE ONCOLOGY

RARE EPILEPSY

RARE SLEEP

NEW RARE THERAPEUTIC AREAS

Rare Disease

- High unmet need
- Small patient populations
- Concentrated call points
- Differentiated support services
- Lower competitive intensity
- Attractive peak revenue opportunity for Jazz
- Favorable regulatory and policy dynamics

How Jazz Will Compete in Rare Disease

Leveraging Expertise to Optimize Future Investments and Growth

- Focus on areas of **significant unmet need**
- Pursue innovative products with **potential to be standards of care**
- Prepared to assume greater clinical risk **within areas of existing expertise**
- Build **$1B+ franchises** with multiple assets to enhance profitability
- Source products from **internal research** and **corporate development**
- Augment our **customer centricity** and **digital / AI capabilities**
- Leverage **strong track record** of acquiring or launching assets in rare disease with **three $1B+ rare disease franchises** (sleep, epilepsy, oncology)

xywav™

Epidiolex® (cannabidiol)

MODEYSO™ (dordaviprone) capsules 125 mg

ZIIHERA® zanidatamab

ZEPZELCA™ (lurbinectedin) for injection 4 mg

Track Record of Success in Rare Disease

Research and Development

ZIIHERA® zanidatamab

$2B+ opportunity that is a cornerstone of our future growth

Commercial

Epidiolex® (cannabidiol)

xywav™

Multiple $1B+ drugs in 2025[1]

Corporate Development

MODEYSO™ (dordaviprone) capsules 125 mg

$500M+ peak potential outperforming initial expectations

[1]Based on 2025 net product sales for Epidiolex and Xywav. Jazz Pharmaceuticals plc has not finalized its financial results for the year ended December 31, 2025, and actual results may differ.

Zanidatamab: High Value, De-Risked Asset with Broad Potential Across Indications

ZIIHERA® zanidatamab

Zanidatamab is a highly active, differentiated HER2-targeted bispecific mAb with compelling survival data

- Novel and Differentiated MOA
- Best-in-Class Profile Addresses Unmet Need
- Compelling Phase 3 Data in 1L GEA
- $2B+ Commercial Opportunity

Positive Phase 3 Data Support Zanidatamab as 1L HER2+ GEA Standard of Care



"The results of the HERIZON-GEA-01 study are **practice-changing**. In addition to the PFS and OS benefits, the remarkably long duration of response and consistent benefit across relevant subgroups, including PD-L1 positive and negative tumors, strongly suggest that zanidatamab plus chemotherapy, with or without tislelizumab, should **become the new standard of care** for patients with HER2+ first-line locally advanced unresectable or metastatic GEA."

Dr. Geoffrey Ku,
Associate Attending Physician on the Gastrointestinal Oncology Service in the Department of Medicine at Memorial Sloan Kettering Cancer Center and study co-author

Data as presented by Elimova et.al ASCO GI 2026.

Progress Towards Realizing Full Potential of Zanidatamab

2026

- Continued execution to **realize full value** of zanidatamab across indications

GEA

- ASCO GI data presentation and peer-reviewed publication
- Potential inclusion in **NCCN guidelines**
- Plan to **submit sBLA** in 1H26
- Potential **approval and launch** in 1L GEA in late 2026

2027 and Beyond

- Expect to **realize full value** with multiple indication expansion opportunities:
  - Pan-tumor, early / metastatic breast cancer, early gastric cancer, CRC, NSCLC
- **Continued data readouts** across indications
- Potential **EmpowHER-BC-303 top-line data** in late 2027 / early 2028

Goal: Become the HER2-targeted therapy of choice and cornerstone of future growth for Jazz

Driving Durable Growth Through Strong Commercial Execution

Epidiolex

Epidiolex®

Standard of care in LGS, DS, and TSC

- ✓ Strong commercial execution achieving **$1B+ in sales**[1] in 2025
- ✓ **Durable** asset with **robust IP protection**
- ✓ **Further development opportunities**, including additional formulation work

Xywav

xywav™

Differentiated low-sodium oxybate

- ✓ Focused on continued commercial execution achieving **$1B+ in sales** in 2025
- ✓ **Only approved drug** to treat IH
- ✓ **Orphan drug exclusivity** into 2028 with multiple orange-book listed patents through 2041

[1]Jazz Pharmaceuticals plc has not finalized its financial results for the year ended December 31, 2025, and actual results may differ.

Enhancing Value Through Acquisition of Chimerix

MODEYSO™ (dordaviprone) capsules 125 mg

2025

- Successfully acquired and integrated Chimerix
- **Modeyso** approval granted **ahead of schedule**
- **Strong early launch performance** with nearly $50M in revenue for 2025[1]
- Future cash taxes reduced by ~$200M (DTA)
- Executed definitive agreement to **sell PRV for $200M** in gross proceeds[2]

2026 and Beyond

Phase 3 ACTION Trial

- Enrollment ongoing and on track; **interim OS data late 2026 / early 2027**
- Potential ex-U.S. **expansion opportunities**

Compelling opportunity with $500M+ peak sales potential

[1]Jazz Pharmaceuticals plc has not finalized its financial results for the year ended December 31, 2025, and actual results may differ; [2]50% net to Jazz.

Well Positioned to Succeed in Rare Disease

Research and Development

Commercial

Corporate Development

Strong Financial Position

$4B+
Total revenues in 2025[1]

$1B+
Cash from operations[2]

$2B+
Cash, cash equivalents, and investments[3]

[1]Jazz Pharmaceuticals plc has not finalized its financial results for the year ended December 31, 2025, and actual results may differ; [2]For the nine months ended September 30, 2025; [3]As of September 30, 2025.

Strong Momentum Into 2026

Research and Development

Zanidatamab

sBLA submission for 1L GEA in **1H26**

Potential approval in 1L GEA **late 2026**

EmpowHER-BC-303 trial top-line readout **late 2027 / early 2028**

Dordaviprone

Phase 3 1L ACTION trial readout **late 2026 / early 2027**

Commercial

MODEYSO™ (dordaviprone) capsules 125 mg

Full-year commercial sales

ZEPZELCA™ (lurbinectedin)

Full-year commercial sales[1] in 1LM ES-SCLC

Epidiolex® (cannabidiol) xywav™

Continued **commercial execution** and data generation

Corporate Development

Identifying and **pursuing** opportunities in **Rare Disease** to drive long-term growth and value

[1]Zepzelca in combination with Tecentriq (atezolizumab).

Jazz Pharmaceuticals®

THANK YOU

Jazz Pharmaceuticals®

Q&A

Glossary

Acronym	Definition
1H26	first half 2026
1L	First-line
1LM	First-line maintenance
AI	Artificial intelligence
ASCO	American Society of Clinical Oncology
ANDA	Abbreviated new drug application
B	billion
CI	Confidence interval
CEO	Chief executive officer
CRC	Colorectal cancer
CT	Chemotherapy
DS	Dravet syndrome
DTA	Deferred Tax Asset
ES-SCLC	Extensive-stage small-cell lung cancer
FDA	U.S. Food and Drug Administration
GEA	Gastroesophageal adenocarcinoma
HER2	Human epidermal growth factor receptor 2
HER2+	Human epidermal growth factor receptor 2 positive

Acronym	Definition
IH	Idiopathic Hypersomnia
IP	Intellectual property
LGS	Lennox-Gastaut syndrome
M	million
mAb	Monoclonal antibody
MOA	Mechanism of action
NCCN	National comprehensive cancer network
NDA	New Drug Application
NSCLC	Non-small cell lung cancer
OS	Overall survival
P	probability
PD-L1	Programmed death-ligand 1
PFS	Progression-free survival
PRV	Priority Review Voucher
R&D	Research and development
sBLA	Supplemental biologics license application
TSC	Tuberous Sclerosis Complex
YE	Year end